Cardiff University | Prifysgol Caerdydd ORCA
Online Research @ Cardiff 
WelshClear Cookie - decide language by browser settings

Tackling gaps in developing life-changing treatments for dementia

Benn, Caroline, Davis, John, Dawson, Lee, Dawson, Gerry, Evans, Alison, Fox, Nick, Gallacher, John, Hutton, Mike, Isaac, John, Jones, Declan, Jones, Lesley, Libri, Vincenzo, Lovestone, Simon, Mauricio, Rui, Moody, Catherine, Noble, Wendy, Perry, Hugh, Pickett, James, Reynolds, David, Ritche, Craig, Rohrer, John, Routledge, Carol, Rowe, James, Snyder, Heather, Spires-Jones, Tara, Swartz, Jina, Truyen, Luc and Whiting, Paul 2019. Tackling gaps in developing life-changing treatments for dementia. Alzheimer's & Dementia: Translational Research & Clinical Interventions 5 , pp. 241-253. 10.1016/j.trci.2019.05.001

[img]
Preview
PDF - Published Version
Available under License Creative Commons Attribution Non-commercial No Derivatives.

Download (312kB) | Preview

Abstract

Since the G8 dementia summit in 2013, a number of initiatives have been established with the aim of facilitating the discovery of a disease-modifying treatment for dementia by 2025. This report is a summary of the findings and recommendations of a meeting titled “Tackling gaps in developing life-changing treatments for dementia”, hosted by Alzheimer's Research UK in May 2018. The aim of the meeting was to identify, review, and highlight the areas in dementia research that are not currently being addressed by existing initiatives. It reflects the views of leading experts in the field of neurodegeneration research challenged with developing a strategic action plan to address these gaps and make recommendations on how to achieve the G8 dementia summit goals. The plan calls for significant advances in (1) translating newly identified genetic risk factors into a better understanding of the impacted biological processes; (2) enhanced understanding of selective neuronal resilience to inform novel drug targets; (3) facilitating robust and reproducible drug-target validation; (4) appropriate and evidence-based selection of appropriate subjects for proof-of-concept clinical trials; (5) improving approaches to assess drug-target engagement in humans; and (6) innovative approaches in conducting clinical trials if we are able to detect disease 10–15 years earlier than we currently do today.

Item Type: Article
Date Type: Publication
Status: Published
Schools: Medicine
MRC Centre for Neuropsychiatric Genetics and Genomics (CNGG)
Publisher: Elsevier
ISSN: 2352-8737
Date of First Compliant Deposit: 3 June 2019
Date of Acceptance: 9 May 2019
Last Modified: 11 Jul 2019 12:55
URI: http://orca-mwe.cf.ac.uk/id/eprint/123032

Actions (repository staff only)

Edit Item Edit Item

Downloads

Downloads per month over past year

View more statistics